DASATINIB PHAROS 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 100 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 100mg - inhibitori de protein-kinaza

DASATINIB PHAROS 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 20 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 20mg - inhibitori de protein-kinaza

DASATINIB PHAROS 70 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 70 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 70mg - inhibitori de protein-kinaza

DASATINIB PHAROS 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 100 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

DASATINIB PHAROS 20 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 20 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 20mg - alte antineoplazice inhibitori de protein-kinaza

DASATINIB PHAROS 70 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib pharos 70 mg

remedica ltd. - cipru - dasatinibum - compr. film. - 70mg - alte antineoplazice inhibitori de protein-kinaza

Dasatinib Accord Uniunea Europeană - română - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Uniunea Europeană - română - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

DASATINIB ALVOGEN 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib alvogen 100 mg

pharmacare premium ltd. - malta - dasatinibum - compr. film. - 100mg - inhibitori de protein-kinaza

DASATINIB ALVOGEN 140 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

dasatinib alvogen 140 mg

pharmacare premium ltd. - malta - dasatinibum - compr. film. - 140mg - inhibitori de protein-kinaza